CDT Equity Inc. (NASDAQ:CDT) Short Interest Update

CDT Equity Inc. (NASDAQ:CDT) was the recipient of a significant growth in short interest during the month of June. As of June 30th, there was short interest totaling 167,688 shares, a growth of 326.9% from the June 15th total of 39,284 shares. Approximately 3.9% of the shares of the stock are sold short. Based on an average trading volume of 36,828,063 shares, the days-to-cover ratio is presently 0.0 days.

CDT Equity Trading Down 3.8%

Shares of CDT stock traded down $0.01 during trading hours on Tuesday, reaching $0.34. The company’s stock had a trading volume of 88,771 shares, compared to its average volume of 3,341,658. The firm’s fifty day simple moving average is $1.03 and its 200 day simple moving average is $13.12. CDT Equity has a one year low of $0.34 and a one year high of $468.00. The stock has a market capitalization of $1.68 million, a P/E ratio of -0.00 and a beta of 1.49.

CDT Equity (NASDAQ:CDT) last posted its quarterly earnings data on Wednesday, April 15th. The company reported $695.11 earnings per share for the quarter.

Wall Street Analysts Forecast Growth

CDT has been the subject of a number of analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of CDT Equity in a research note on Wednesday, June 24th. Wall Street Zen downgraded CDT Equity to a “strong sell” rating in a research note on Saturday, June 27th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

CDT Equity Company Profile

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.